CEVA Tiergesundheit (Riems) GmbH, based in Greifswald, is an internationally active biotechnology company operating primarily in the pharmaceuticals, vaccines and animal health segments. The company's purpose is the development, production and distribution of medicinal products—particularly vaccines, serum and hormone preparations for veterinary and human medicine—along with chemical-analytical and biological testing, animal trials and contract manufacturing of medicines and cosmetics. The company acts as a contract manufacturer and research service provider for the parent company CEVA Santé Animale S.A. and runs an established Lead Generation unit focused on swine vaccines in cooperation with external partners such as the Friedrich-Loeffler-Institut and the CEVA Innovation Center.
die Entwicklung, die Produktion und der Vertrieb von Arzneimitteln, insbesondere von Impfstoffen, Serum- und Hormonpräparaten für die Vetrerinär- und Humanmedizin und von Erzeugnissen aller Art, die aus Mikroorganismen und aus anderen Naturstoffen gewonnen werden sowie die Durchführung von chemischanalytischen und biologischen Untersuchungen, Tierversuchen und die Lohnfertigung von Arzneimitteln und Kosmetikerzeugnissen
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Stralsund Local Court, HRB 21134 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| George Basrawi | Geschäftsführer(in) | Rheinfelden (Baden) |
Source: German Commercial Register (Handelsregister) Stralsund Local Court, HRB 21134 (as of 31 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 16.07.2020 | Gesellschaftsvertrag created | Gesellschaftsvertrag |
| 13.12.2019 | Company Name Registered | Ceva Tiergesundheit (Riems) GmbH |
| 13.12.2019 | Registered Seat | Greifswald |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 13.12.2019 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Stralsund Local Court, HRB 21134 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€17.1M2 | €849,262 | €48,258,477 | — |
| 2024 | Rohergebnis€17.5M2 | €1,954,407 | €45,878,190 | — |
| 2023 | Rohergebnis€14.7M2 | -€890,100 | €42,030,991 | — |
| 2022 | Rohergebnis€11.9M2 | -€1,669,787 | €41,479,716 | — |
| 2021 | Rohergebnis€10.3M2 | €105,137 | €44,067,782 | — |
| 2020 | Rohergebnis€10.5M2 | €1,767,768 | €38,751,049 | — |
| 2019 | €14,148,668 | €309,496 | €36,457,910 | — |
| 2018 | €10,596,000 | -€2,502,000 | €32,642,000 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Stralsund Local Court, HRB 21134 (as of 31 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €8,421,379 | 78.4% |
| Depreciation | €2,092,900 | 19.5% |
| Interest & Similar | €231,136 | 2.2% |
